OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


2009 & 2005 Program Project Development Grant Recipient – Anil Sood

Anil Sood, M.D.
MD Anderson Cancer Center
Novel Treatments for Ovarian Cancer Using siRNAS

Project Summary

Dr. Sood aims to develop new types of treatments for ovarian cancer using short interfering RNA or siRNA approaches. siRNA molecules are part of a natural, selective process inside cells that turn off genes. Their potential for becoming new drugs is being highly investigated. In this study, Dr. Sood will use siRNA in three projects:

  1. He will use siRNA to turn off a specific gene called FAK, believed to be overexpressed in ovarian cancer. He will put the siRNA in a liposome, or a microscopic fatty carrier, to release the drug into diseased tissue.
  2. He will put siRNAs that turn off the genes ATP7A and ATP7b, believed to play a role in resistance to platinum drugs, into a liposome to try to overcome the drug’s resistance and
  3. He will try to develop new carriers for siRNAs so they target ovarian cancer rather than normal tissue and remain in the diseased tissue longer.


Dr. Sood joined M.D. Anderson in 2002 and is a physician scientist and Director of Ovarian Cancer Research. He has a joint appointment in the Department of Cancer Biology and maintains a laboratory where his research focuses on mechanisms of cancer invasion and metastasis in ovarian cancer.

Specifically, Dr. Sood’s research is focused in three areas: 1) effect of neuroendocrine stress hormones on ovarian cancer growth and progression; 2) development of novel anti-vascular therapeutic approaches; and 3) development of new strategies for in vivo siRNA delivery. His research is funded by the National Cancer Institute and the Department of Defense.

Dr. Sood received an undergraduate degree from Davidson College in Pre-Medicine. He received his medical degree from the University of North Carolina. After completing his residency in Obstetrics and Gynecology at the University of Florida at Gainesville, he completed a Fellowship in Gynecologic Oncology at the University of Iowa.

Catching Ovarian Cancer Early May Miss Aggressive Tumors